부산대학교 도서관

Nine out of the 75 patients had a documented hypersensitivity reaction to etoposide and underwent 22 cycles of desensitization to etoposide. Given the urgency for treatment and the shortage of the water-soluble prodrug of etoposide, etoposide phosphate, confirmatory skin testing for etoposide was not an option at the time; therefore, our multi-disciplinary team successfully developed a 13-step and a 15-step etoposide desensitization protocol to safely provide etoposide per the individual's oncology treatment protocol. In the setting of a national shortage of etoposide phosphate, we report a standardized 13- and 15-step etoposide desensitization protocol that is both safe and effective in the treatment of pediatric oncology patients who have experienced HSRs to etoposide. [Extracted from the article]